Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: JanyBlueEyes who wrote (574)	12/10/1997 8:46:00 PM
From: baggo	Respond to of 5736

Jane, Thanks for your reply. I think we were "responding" at the same time. My thoughts are that if CCSI product is noninvasive and relatively CHEAP more testing may be done. Cost containment in health care arena is unbelievable,though!! Good luck, Brice Guckien

To: JanyBlueEyes who wrote (574)	12/10/1997 10:25:00 PM
From: R. M. Rosenthal	Read Replies (2) \| Respond to of 5736

Janybird: I am very long CCSI but need some help. From your post #469, Nov 11 1997 quoting: INVESTOR FACT SHEET - RESEARCH MAGAZINE 10/97: >> CHROMATICS TARGETS BILIRUBIN How Common Is Bilirubin? Bilirubin affects more than half of all the babies born and nearly 100 percent of all premature children. Every infant born is monitored for it.<< From above: >> According to World Health Organization published figures approximatley 4,000,000 babies are born per year and approximately 10% of babies are born premature.This equals 3,600,000 full term,and 400,000 premature.<< As this relates directly to market size, I'd sure appreciate some clarification. Many thanks and my compliments for your most extraordinary efforts here and elsewhere. RMR